ImmPACT Bio Announces Abstract Accepted for Poster Presentation at the Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting
LOS ANGELES, Calif., November 1, 2023 – ImmPACT Bio USA, Inc. (“ImmPACT BIO”), a clinical-stage company developing transformative logic-gate-based chimeric antigen receptor (CAR) T-cell therapies for treating cancer and autoimmune diseases, today announced an abstract has been accepted for poster presentation at the Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting, to be held from November, 1-5, 2023 in San Diego, CA.
ImmPACT Bio’s Michael Weist, Ph.D. will present a poster on the Company’s TGF-β CAR platform technology and the potential capacity to improve the function and persistence of TCR therapies in the tumor microenvironment (TME).
Title: Enhancing TCR-T responses and overcoming the tumor microenvironment by combination with a TGFβ-specific CAR
Abstract Number: 442-I
Date / Time: Saturday, November 4 from 7:00 – 8:30 P.M. Pacific Time
Location: Exhibit Halls A and B1 – San Diego Convention Center
Abstract titles are now available on the SITC website. Posters will be made available on the ImmPACT website following presentation at the conference.
About ImmPACT Bio
ImmPACT Bio USA, Inc., is a clinical-stage company dedicated to the discovery of transformative chimeric antigen receptor (CAR) T-cell therapies that address key biological challenges in treating cancer and autoimmune diseases. The company’s logic-gate-based CAR T-cell platforms, licensed from University of California, Los Angeles (UCLA) Technology Development Group, are specifically designed to prevent antigen escape, overcome the immunosuppressive tumor microenvironment, and deplete pathogenic B cells. The company’s technology is based on the work of pioneering scientists Yvonne Chen, Ph.D., and Antoni Ribas, M.D., Ph.D., both from UCLA. For more information, visit www.immpact-bio.com.
Contacts for inquiries or additional information: